• Funda Coşkun, Aykut Çilli, İsmail Hanta, Can Sevinç, Ayşe Ödemiş, and Ahmet Ursavaş.
• Department of Chest Diseases, Faculty of Medicine, Bursa Uludağ University, Bursa, Turkey
• Turk J Med Sci. 2021 Dec 13; 51 (6): 308230883082-3088.

Background/AimPhase III trials have demonstrated a significant efficacy and an acceptable safety for pirfenidone in patients having mild to moderate idiopathic pulmonary fibrosis (IPF). Real-life data on the use of pirfenidone 200 mg tablets are limited. This study aimed to investigate the efficacy and safety of pirfenidone 200 mg tablets for the treatment of IPF in a real-life setting.Materials And MethodsA retrospective, multicenter study conducted in four university hospitals in Turkey between January 2017 and January 2019. Clinical records of patients diagnosed with mild to moderate IPF and receiving pirfenidone (200 mg tablets, total 2400 mg/day) were reviewed retrospectively and consecutively. Pulmonary function measurements including forced vital capacity (FVC%) and diffusing capacity of the lungs for carbon monoxide (DLCO%) were analyzed at baseline and after 6-month of pirfenidone treatment. Descriptive statistics were expressed as mean, standard error or median (minimum-maximum), number and percentage, where appropriate.ResultsThe study included 82 patients, of whom 87.8% were males (mean age, 66 years). After 6-month of treatment, 7 patients discontinued the treatment. Of the remaining 75 patients, 71 (94.6%) remained stable, 4 (5.4%) had progressive disease as evident by a decline in the FVC% of at least 10% while on treatment, and 45 (61.3%) had improved cough. At least one adverse event (AE) associated with the treatment was observed in 28 (37.3%) patients.ConclusionPirfenidone 200 mg was effective and well tolerated and associated with relatively mild and manageable AEs in IPF patienThis work is licensed under a Creative Commons Attribution 4.0 International License.

24 keywords...

hide…